Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Platinol patent extends to 2012 following Oct. 8 cisplatin patent issuance, 26 years after filing.

Executive Summary

BRISTOL PLATINOL (CISPLATIN) BASIC PATENT RUNS TO MAY 8, 2012 following the issuance of U.S. Patent No. 5,562,925 for the compound on Oct. 8. The patent was granted by the Patent & Trademark Office to Tucson, Ariz.-based Research Corporation Technologies, which licenses the patent to Bristol. Cisplatin is already protected by a use patent which expires Dec. 4.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029025

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel